Torossian Avedis, Genoux Annelise, Cai Zichun, Jolivet Nathan, Croyal Mikaël, Oliveira Arsênio Rodrigues, Dejean Sébastien, Viguerie Nathalie, Cabou Cendrine, Perret Bertrand, Ferrières Jean, Bongard Vanina, Martinez Laurent O
Faculté de Santé, Université Toulouse 3, Toulouse, France.
Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, UMR1297, Inserm, Université de Toulouse, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France.
Atheroscler Plus. 2025 May 8;60:35-42. doi: 10.1016/j.athplu.2025.04.003. eCollection 2025 Jun.
BACKGROUND AND AIMS: The role of many apolipoproteins in cardiovascular disease (CVD) pathophysiology and their predictive potential remains unclear. This study examined the association between plasma concentrations of a broad panel of apolipoproteins and the occurrence of cardiovascular events in a general population. METHODS: A nested case-control study was conducted within a cohort from Southwestern France. Baseline concentrations of apolipoproteins A-I, A-II, A-IV, B100, C-I, C-II, C-III, D, E, H, J, L1 and M were analyzed in 65 cases who experienced a cardiovascular event during the follow-up period, and in 65 controls matched for age and sex (mean age 60.9 ± 10.7 years; 66.9 % men; median follow up 9.3 years for controls, 6.2 years for cases). Baseline correlations were assessed using Spearman's coefficients.Logistic regression and partial least squares discriminant analysis (PLS-DA) were used to evaluate associations with the occurrence of cardiovascular events. RESULTS: Concentrations of apolipoproteins A-I, A-IV, C-I, D, H, J and M differed significantly between cases and controls. All expect apoM remained independently associated with cardiovascular events after adjustment for known risk factors. Additionally, PLS-DA revealed that the entire apolipoprotein panel explained 64 % of variance in case-control status with 60 % predictive accuracy, with apolipoproteins D, J, A-IV, H, and C-I contributing the most to group discrimination. CONCLUSIONS: This study identifies a novel panel of apolipoproteins (A-I, A-IV, C-I, D, H, and J) whose levels are associated with occurrence of cardiovascular diseases, independently of traditional risk factors. Further research is needed to confirm these findings and explore underlying mechanisms.
背景与目的:许多载脂蛋白在心血管疾病(CVD)病理生理学中的作用及其预测潜力仍不明确。本研究调查了一组广泛的载脂蛋白的血浆浓度与普通人群心血管事件发生之间的关联。 方法:在法国西南部的一个队列中进行了一项巢式病例对照研究。对随访期间发生心血管事件的65例患者以及65例年龄和性别匹配的对照者(平均年龄60.9±10.7岁;66.9%为男性;对照组中位随访时间为9.3年,病例组为6.2年)的载脂蛋白A-I、A-II、A-IV、B100、C-I、C-II、C-III、D、E、H、J、L1和M的基线浓度进行了分析。使用Spearman系数评估基线相关性。采用逻辑回归和偏最小二乘判别分析(PLS-DA)来评估与心血管事件发生的关联。 结果:病例组和对照组之间载脂蛋白A-I、A-IV、C-I、D、H、J和M的浓度存在显著差异。在对已知危险因素进行调整后,除载脂蛋白M外,所有其他载脂蛋白仍与心血管事件独立相关。此外,PLS-DA显示,整个载脂蛋白组解释了病例对照状态64%的方差,预测准确率为60%,其中载脂蛋白D、J、A-IV、H和C-I对组间区分贡献最大。 结论:本研究确定了一组新的载脂蛋白(A-I、A-IV、C-I、D、H和J),其水平与心血管疾病的发生相关,且独立于传统危险因素。需要进一步研究来证实这些发现并探索潜在机制。
Cardiovasc Diabetol. 2022-2-7
Front Endocrinol (Lausanne). 2022
Cardiovasc Res. 2024-2-17
CMAJ. 2023-8-28
Antioxidants (Basel). 2023-4-28
Cardiovasc Diabetol. 2022-12-5
J Am Coll Cardiol. 2022-12-20
Front Cardiovasc Med. 2022-6-30
Front Physiol. 2021-10-7